(Q38305705)

English

Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy

scientific article published on 03 January 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

author name string

Heather L Blackburn

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Darrell L Ellsworth

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Craig D Shriver

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Rachel E Ellsworth

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

3 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Cancer Causes & Control

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

319-332

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Clinical importance of the cytochromes P450

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Pharmacogenetics of the cytochromes P450.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Oral cancer and polymorphism of ethanol metabolising genes.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Cytochrome P450-mediated metabolism of estrogens and its regulation in human.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP17, catechol-o-methyltransferase, and glutathione transferase M1 genetic polymorphisms, lifestyle factors, and breast cancer risk in women on Prince Edward Island.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Association between CYP17 gene polymorphism and risk of breast cancer in young women.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Breast cancer: a candidate gene approach across the estrogen metabolic pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP17 gene polymorphism in relation to breast cancer risk: a case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Polymorphic variation in CYP19 and the risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Aromatase and breast cancer susceptibility

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Polymorphisms associated with circulating sex hormone levels in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Human aromatase: gene resequencing and functional genomics

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Increased cell proliferation is associated with genomic instability: elevated micronuclei frequencies in estradiol-treated human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Repair of oxidative damage to DNA: enzymology and biology

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Oxidative DNA modifications

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: implications for hormonal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Carcinogenicity of catechol estrogens in Syrian hamsters

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women.

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

The biology of breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Metastatic behavior of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Tamoxifen and CYP2D6: a contradiction of data

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Tamoxifen, antidepressants, and CYP2D6: the conundrum continues

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

The ethics of CYP2D6 testing for patients considering tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Drug and hormone interactions of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Environmental chemicals and breast cancer risk--a structural chemistry perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

CYP1B1 and predisposition to breast cancer in Poland

1 reference

https://api.crossref.org/works/10.1007%2FS10552-014-0519-7

21 January 2018

Identifiers

10.1007/S10552-014-0519-7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38305705&oldid=2201543832"